article Open AccessTop 1% cited
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
The Lancet Oncology · 2017 · Vol. 18(10) · pp. 1307–1316
David Planchard(Institut Gustave Roussy)Egbert F. Smit(Vrije Universiteit Amsterdam)Harry J.M. Groen(University of Groningen)Julien Mazières(Université Toulouse III - Paul Sabatier)Benjamin Besse(Institut Gustave Roussy)Åslaug Helland(Oslo University Hospital)Vanessa Giannone(Novartis (United States))Anthony M. D’Amelio(Novartis (United States))Pingkuan Zhang(Novartis (United States))Bijoyesh Mookerjee(Novartis (United States))Bruce E. Johnson✉(Dana-Farber Cancer Institute)
Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsSynthesis and biological activityTrametinibDabrafenibMedicineInternal medicineClinical endpointLung cancerAdverse effectPopulationOncologyPhases of clinical research
MeSH terms
Administration, OralAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugDrug Administration ScheduleHumansImidazolesLung NeoplasmsMiddle AgedMutationNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingOximes
Funding
- GlaxoSmithKline
- Novartis
- Novartis Pharmaceuticals Corporation
Citations
1,350
FWCI
61.45
field-weighted impact
References
53
Percentile
100%
vs. same field & year
Citations per year
Cited by
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Cancers · 2019 · 925 citations
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 2,268 citations
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Annals of Oncology · 2020 · 1,151 citations
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Mayo Clinic Proceedings · 2019 · 2,172 citations
References
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
The Lancet Oncology · 2012 · 5,500 citations
Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Clinical Cancer Research · 2014 · 776 citations
Mutations of the BRAF gene in human cancer
Nature · 2002 · 10,619 citations
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
The Lancet Oncology · 2014 · 1,963 citations
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet · 2015 · 6,477 citations
Cancer statistics, 2016
CA A Cancer Journal for Clinicians · 2016 · 16,130 citations
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Clinical Cancer Research · 2016 · 1,214 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.